Search

Your search keyword '"Bisagni, G"' showing total 345 results

Search Constraints

Start Over You searched for: Author "Bisagni, G" Remove constraint Author: "Bisagni, G"
345 results on '"Bisagni, G"'

Search Results

101. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).

102. Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.

103. Abstract P5-12-05: 9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER

105. Safety and Activity Report of a Randomized Phase II Trial of Preoperative Anthracycline-Based Chemotherapy Plus Lapatinib, Trastuzumab or Both in HER2 Positive Breast Cancer: CHERLOB Trial.

106. Preplanned first-step analysis of LET-LOB neoadjuvant study: A double-blind randomized phase IIb trial of letrozole (L) plus lapatinib (Lp) or placebo (P) in postmenopausal HER2-ve, HR+ve operable breast cancer

107. Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study

112. Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian oncology group for clinical research (goirc)

113. Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole★.

115. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC)

117. P86 Epirubicin as a single agent in comparison to CMF in adjuvant therapy of stage I and II breast cancer

119. 721 Hydroxyurea (HU), high dose folinic acid (L-FA) and 5FU VS HU, 5FU and interferon-alfa-2B (IFN) in advanced colorectal cancer (ACRC): A randomized trial of the italian oncology group for clinical research (GOIRC)

121. Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.

127. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.

128. A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)

132. 186O Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

138. 721 Hydroxyurea (HU), high dose folinic acid (L-FA) and 5FU VS HU, 5FU and interferon-alfa-2B(IFN) in advanced colorectal cancer (ACRC): A randomized trial of the italian oncology group for clinical research (GOIRC)

139. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

140. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

141. 124 (PB-124) Poster - Adjuvant endocrine therapy choices in premenopausal patients with estrogen receptor-positive early breast cancer: insights from the GIM23-POSTER study.

142. 3 Young Investigator Awardee - Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella (GIM) and Mammella Intergruppo trials (MIG).

143. Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

144. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

145. Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole★.

146. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

147. Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

148. 95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC)

149. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy

150. Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

Catalog

Books, media, physical & digital resources